These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17175489)

  • 41. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
    European Recombinant LH Study Group
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stop GnRH-Agonist Combined With Multiple-Dose GnRH-Antagonist Protocol for Patients With "Genuine" Poor Response Undergoing Controlled Ovarian Hyperstimulation for IVF.
    Orvieto R; Kirshenbaum M; Galiano V; Elkan-Miller T; Zilberberg E; Haas J; Nahum R
    Front Endocrinol (Lausanne); 2020; 11():182. PubMed ID: 32528403
    [No Abstract]   [Full Text] [Related]  

  • 44. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.
    Huang TC; Huang MZ; Seow KM; Yang IJ; Pan SP; Chen MJ; Hwang JL; Chen SU
    Sci Rep; 2021 Nov; 11(1):22732. PubMed ID: 34815477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
    Diedrich K; Diedrich C; Santos E; Zoll C; al-Hasani S; Reissmann T; Krebs D; Klingmüller D
    Hum Reprod; 1994 May; 9(5):788-91. PubMed ID: 7929723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study.
    Felberbaum RE; Albano C; Ludwig M; Riethmüller-Winzen H; Grigat M; Devroey P; Diedrich K
    Hum Reprod; 2000 May; 15(5):1015-20. PubMed ID: 10783344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New Perspectives on Criteria for the Determination of HCG Trigger Timing in GnRH Antagonist Cycles.
    Hu X; Luo Y; Huang K; Li Y; Xu Y; Zhou C; Mai Q
    Medicine (Baltimore); 2016 May; 95(20):e3691. PubMed ID: 27196479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin-releasing hormone antagonist ovarian stimulation protocol.
    Geng Y; Lai Q; Xun Y; Jin L
    Int J Gynaecol Obstet; 2018 Jul; 142(1):97-103. PubMed ID: 29542120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
    Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
    Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
    Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
    Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer.
    Huang SY; Huang HY; Yu HT; Wang HS; Chen CK; Lee CL; Soong YK
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):432-5. PubMed ID: 22212313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of a lower-dose cetrorelix acetate protocol on in-vitro fertilization outcome.
    Tzeng CR; Chen HJ; Lin YH; Hsieh BC; Huang LW; Hwang JL
    Int J Gynaecol Obstet; 2008 Mar; 100(3):271-4. PubMed ID: 18045601
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation.
    Tiboni GM; Palumbo P; Leonzio E; Gabriele E; Verna I; Giampietro F
    Gynecol Endocrinol; 2011 Nov; 27(11):885-9. PubMed ID: 21500992
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
    Tur-Kaspa I; Ezcurra D
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1323-36. PubMed ID: 19761413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Kalogeropoulou L; Papanikolaou E; Tarlatzis BC
    Fertil Steril; 2011 Feb; 95(2):558-62. PubMed ID: 20637457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.
    Hwang JL; Chen SU; Chen HJ; Chen HF; Yang YS; Chang CH; Seow KM; Tzeng CR; Lin YH
    J Formos Med Assoc; 2018 Jun; 117(6):535-540. PubMed ID: 28830648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.